BIIB · BIOGEN INC.

423 filings

BIIB SEC Filings

BIOGEN INC. - 423 total filings

Filing record · 2016–202610-K1110-Q328-K112

Showing 1–50 of 423 filings

BIOGEN INC. 8-K Report, Financial Results (Jul 29, 2026)

Biogen reported second quarter 2026 total revenue of $2.74 billion, up 3% year-over-year (2% at constant currency). Growth Portfolio revenue reached $1.06 billion, up 24%, and exceeded Legacy MS revenue of $767 million for the first time, which management presents as evidence of the company's repositioning. Product-level results were mixed: SKYCLARYS (+29%), ZURZUVAE (+53%), EMPAVELI (+123%) and LEQEMBI global in-market sales (+15%) grew strongly, while MS product revenue fell 13% and VUMERITY declined 7% on inventory dynamics. SYFOVRE and EMPAVELI contributed revenue after the Apellis acquisition closed on May 14, 2026. Profitability fell sharply. GAAP diluted EPS was $0.66 versus $4.33 a year ago, and Non-GAAP diluted EPS was $3.60 versus $5.47, reflecting $164 million of acquired IPR&D and milestone expense, higher SG&A from Apellis and launch spending, and higher interest expense tied to the transaction financing. Free cash flow was $408 million, and net debt stood at about $6.8 billion at June 30, 2026, after total debt rose to roughly $8.1 billion. Full-year 2026 guidance is internally split. Underlying Non-GAAP EPS guidance was raised $0.60 to $15.85 to $16.85, but reported Non-GAAP guidance was cut to $12.00 to $13.00 from $15.25 to $16.25. The reduction reflects roughly $3.00 of acquired IPR&D and milestone charges and about $0.85 of Apellis dilution. Management expects the deal to be accretive in 2027, with run-rate synergies of at least $250 million exiting 2027, and it guides to five registrational readouts over the next four quarters.

Jul 29, 2026 10-Q

BIOGEN INC. Quarterly Report for Q2 Ended Jun 30, 2026

Biogen Inc. reported total revenue of $2.74 billion for the three months ended June 30, 2026, a 3.4% increase from the prior year period. This growth was primarily driven by the inclusion of new specialized immunology products, SYFOVRE and EMPAVELI, acquired through the Apellis acquisition, and strong performance in rare disease products like SPINRAZA and SKYCLARYS. However, revenue from the Multiple Sclerosis portfolio, particularly TECFIDERA, saw a significant decline due to ongoing generic competition. Net income for the quarter was $97.5 million, a substantial decrease compared to $634.8 million in the same period last year, largely due to increased costs associated with the Apellis acquisition, including higher cost of sales, R&D expenses, and significant restructuring charges related to the integration. For the six months ended June 30, 2026, total revenue rose by 2.7% to $5.21 billion, while net income decreased to $417.0 million from $875.3 million in the prior year. The company's operational expenses saw a notable increase, driven by higher amortization from inventory step-ups, increased R&D spending on late-stage programs, and the expanded commercial operations of Apellis. Despite these cost pressures and the continued decline in the MS franchise, the company is focused on the growth of its rare disease and specialized immunology portfolios and strategic investments in its pipeline.

Jul 29, 2026 8-K

BIOGEN INC. 8-K Report, Financial Results (Jul 1, 2026)

Biogen Inc. (BIIB) has filed a Form 8-K on July 1, 2026, to provide preliminary updates on its expected financial results for the second and third quarters of 2026. The primary driver of the disclosed impact is acquired in-process research and development (IPR&D), upfront, and milestone expenses related to collaborations and license agreements. These costs are significant and are expected to impact both GAAP and non-GAAP earnings per diluted share. For the second quarter of 2026, Biogen anticipates an IPR&D expense of approximately $164 million pre-tax, translating to an impact of roughly $0.95 per diluted share. Looking ahead to the third quarter of 2026, the company expects a broader range of IPR&D expenses, estimated between $290 million and $320 million, which could affect earnings per diluted share by approximately $1.75 to $1.95. Investors should note that these are preliminary estimates and are subject to change as financial closing procedures are completed.

Jul 1, 2026 8-K

BIOGEN INC. 8-K/A Report, Exhibit Filing (Jun 10, 2026)

Biogen Inc. (BIIB) has filed an amendment to its previous 8-K filing dated May 14, 2026. The company is clarifying that the previously disclosed acquisition of Apellis Pharmaceuticals, Inc. did not constitute a "significant" acquisition under Regulation S-X. Consequently, Biogen will not be filing the financial statements of Apellis or the pro forma financial information related to the merger as initially anticipated. This amendment is primarily an administrative update to correct the reporting requirements associated with the Apellis acquisition. Investors should note that this filing does not alter the fundamental terms or completion of the acquisition itself, but rather clarifies the regulatory reporting obligations post-transaction. The original disclosures regarding the consummation of the merger remain unchanged.

Jun 10, 2026 8-K

BIOGEN INC. 8-K Report, Shareholder Vote Results (Jun 10, 2026)

Biogen Inc. (BIIB) filed an 8-K on June 10, 2026, reporting the final voting results from its 2026 Annual Meeting of Stockholders held on June 9, 2026. The meeting's primary outcomes included the election of ten directors to the Board and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Additionally, stockholders provided an advisory vote on executive compensation. Investors can view the detailed voting outcomes for each director nominee, which indicate overwhelming support for most candidates, with a few exceptions receiving notably fewer 'for' votes but still comfortably elected. The ratification of the auditor and the advisory vote on executive compensation also received significant stockholder approval, suggesting general confidence in the company's governance and financial oversight for the upcoming fiscal year.

Jun 10, 2026 8-K

BIOGEN INC. 8-K Report, Material Agreement (May 14, 2026)

Biogen (BIIB) has completed its acquisition of Apellis Pharmaceuticals (APLS), a deal announced March 31, 2026. The tender offer expired May 13, 2026, with about 105.7 million shares tendered (roughly 82.4% of outstanding shares), satisfying the minimum condition. Purchaser accepted the shares for payment on May 14, 2026, and Apellis was merged into a Biogen subsidiary under DGCL Section 251(h) without a stockholder vote. Shareholders receive $41.00 in cash plus one non-transferable contingent value right (CVR) per share. The total cash outlay is about $5.3 billion, excluding fees and CVR payments, and Biogen estimates up to about $582 million more if all CVR milestones are met. Management says the deal adds EMPAVELI and SYFOVRE, which generated $689 million in combined 2025 net product revenue, and expects it to be accretive to non-GAAP EPS in 2027. Updated guidance is due with Q2 earnings in July. Financing is a $2 billion unsecured term loan from U.S. Bank, signed May 12, 2026 and fully drawn May 13. It has a $1 billion 364-day Tranche A (SOFR plus 0.75%, due May 2027) and a $1 billion two-year Tranche B (SOFR plus 0.75%–1.00%, due May 2028). Biogen must keep consolidated leverage at or below 3.75x, temporarily flexible to 4.25x after material acquisitions. The added debt and the CVR obligations will weigh on the balance sheet until the loans are repaid or refinanced. The CVRs pay $2.00 per share if SYFOVRE annual net sales reach $1.5 billion in any of 2027–2030, and a further $2.00 per share if sales reach $2.0 billion in any of 2027–2031. The second milestone pays $4.00 instead if the first is missed by 2030 and the second is hit in 2031. Each milestone pays only once, and there is no assurance either will be achieved. Investors should note that the filing refers to the deal's $4 maximum CVR value as conditional on SYFOVRE sales, which is a real risk given the product's current scale.

May 14, 2026 8-K

BIOGEN INC. 8-K Report, Financial Results (Apr 29, 2026)

Biogen reported first-quarter 2026 total revenue of $2.48 billion, up 2% year-over-year as reported but down 2% at constant currency. GAAP diluted EPS was $2.15 (up 31%) and non-GAAP diluted EPS was $3.57 (up 18%). Growth products rose 12%, led by LEQEMBI global in-market sales of $168 million (up 74%), ZURZUVAE (up 100%) and QALSODY (up 110%). The MS franchise was roughly flat, and SPINRAZA declined 12% on the timing of ex-U.S. shipments. Q1 also benefited from roughly $40 million of favorable U.S. TYSABRI discount and allowance adjustments and $19 million of favorable ex-U.S. TYSABRI inventory timing. The headline news is the proposed acquisition of Apellis Pharmaceuticals, which Biogen expects to close in the second quarter of 2026 and which it says will be accretive in 2027 and materially lift non-GAAP EPS compound annual growth through the end of the decade. Biogen also agreed to acquire exclusive Greater China rights to felzartamab from TJ Biopharma. Together these deals carry an approximately $1.00 per share acquired IPR&D charge, so full-year 2026 non-GAAP diluted EPS guidance was lowered to $14.25 to $15.25 from $15.25 to $16.25. The guidance excludes Apellis, and Biogen expects to issue a combined update with Q2 results. Full-year 2026 revenue is now expected to decline by a mid-single-digit percentage. Balance sheet and cash flow remain solid. Operating cash flow was $646 million and free cash flow was $594 million. Total debt was about $6.3 billion and net debt about $1.5 billion. Investors will want to track Apellis financing and closing conditions, the durability of growth-product momentum against MS erosion, and the pace of late-stage pipeline readouts for litifilimab and felzartamab.

Apr 29, 2026 10-Q

BIOGEN INC. Quarterly Report for Q1 Ended Mar 31, 2026

Biogen Inc. reported solid financial results for the first quarter of 2026, demonstrating revenue growth and improved profitability. Total revenue increased by 1.9% to $2,477.8 million, driven primarily by growth in revenue from anti-CD20 therapeutic programs and the Alzheimer's collaboration. Net income attributable to Biogen Inc. saw a significant increase of 33.1% to $319.5 million, leading to diluted earnings per share of $2.15, up from $1.64 in the prior year. This improvement was supported by a decrease in total costs and expenses, notably a significant reduction in acquired in-process research and development expenses. The company also maintained a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $4.7 billion. Furthermore, Biogen announced a significant development with an agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expected to enhance its immunology and rare disease portfolio.

Apr 29, 2026 8-K

BIOGEN INC. 8-K Report, Financial Results (Apr 6, 2026)

Biogen Inc. has filed an 8-K report on April 6, 2026, to provide preliminary insights into its first quarter 2026 financial results. The company anticipates recognizing approximately $34 million in pre-tax acquired in-process research and development (R&D), upfront, and milestone expenses. This is expected to negatively impact both GAAP and non-GAAP earnings per diluted share by approximately $0.19 for the quarter. These expenses are typically associated with collaboration and licensing agreements, including upfront and milestone payments, and can also involve premiums on equity securities or asset acquisitions related to in-process R&D. Biogen notes that such expenses are inherently difficult to forecast due to the unpredictable nature of future transactions. Investors should consider this a preliminary disclosure, as final results are subject to financial statement closing procedures and may differ.

Apr 6, 2026 8-K

BIOGEN INC. 8-K Report, Material Agreement (Mar 31, 2026)

On March 31, 2026, Biogen (BIIB) agreed to acquire Apellis Pharmaceuticals (APLS) through a two-step transaction: a cash tender offer at $41.00 per share, followed by a second-step merger under DGCL Section 251(h) with no stockholder vote required. The upfront equity value is approximately $5.6 billion. Each Apellis share also receives one non-transferable contingent value right (CVR) worth up to $4.00 in cash, tied to annual global net sales of SYFOVRE®: $2.00 if sales reach $1.5 billion in any year from 2027 to 2030, a further $2.00 if sales reach $2.0 billion in any year from 2027 to 2030, or $4.00 if the $2.0 billion threshold is first met in 2031 (and the $1.5 billion milestone was not previously met by December 31, 2030). Each milestone pays only once. The deal is financed with roughly $3.6 billion of cash on hand and about $2 billion of revolving credit and bank loans, and Biogen expects to de-lever by year-end 2027. The strategic rationale centers on Apellis's two marketed complement-inhibitor products, EMPAVELI® and SYFOVRE®, which generated combined 2025 net product revenue of $689 million and are expected to grow in the mid-to-high teens at least through 2028. The acquisition also gives Biogen U.S. nephrology commercial infrastructure ahead of a potential felzartamab launch, with the first Phase 3 readout expected in the first half of 2027. Management expects the deal to be increasingly accretive to non-GAAP diluted EPS starting in 2027 and to meaningfully raise Biogen's non-GAAP EPS CAGR through the end of the decade. Biogen plans to update full-year 2026 guidance with its Q1 2026 earnings. Closing is expected in the second quarter of 2026, subject to the tender offer minimum condition (a majority of outstanding shares), HSR clearance, and other customary conditions. The agreement includes a $205 million termination fee payable by Apellis in specified circumstances, including a superior proposal or a withdrawal of board recommendation. The outside date for the tender offer is September 30, 2026. Support stockholders holding about 14% of Apellis shares, including Morningside Venture Investments and several Apellis directors and officers, have agreed to tender and vote in favor, which provides meaningful deal certainty. The filing does not disclose the offer's commencement date, which is still pending.

Mar 31, 2026 8-K

BIOGEN INC. 8-K Report, Executive Changes (Mar 11, 2026)

Biogen Inc. (BIIB) has announced a key executive change via an 8-K filing dated March 11, 2026. Susan H. Alexander, the Company's Chief Legal Officer, will be departing her role effective at the end of May 2026. This transition marks the end of Ms. Alexander's tenure in a critical leadership position within the organization. The Company has confirmed that a search process is underway to recruit a successor for the Chief Legal Officer position. Investors should monitor the Company's communication for updates on the appointment of a new CLO, as this role is integral to legal and regulatory compliance, strategic decision-making, and risk management. The timing and profile of the incoming CLO could provide insights into Biogen's future strategic direction and governance.

Mar 11, 2026 8-K

BIOGEN INC. 8-K Report, Executive Changes (Feb 11, 2026)

Biogen Inc. (BIIB) announced a significant leadership transition in its latest 8-K filing. Caroline Dorsa, the current Chair of the Board, will not seek re-election at the upcoming 2026 Annual Meeting of Stockholders. The company has clarified that this decision is amicable and not driven by any disputes regarding Biogen's operations, policies, or practices. This change marks the end of Ms. Dorsa's tenure as Chair, a position she has held, and signals a shift in board leadership for the biotechnology firm. In conjunction with this change, the Board has elected Dr. Maria C. Friere to succeed Ms. Dorsa as the Chair of the Board, effective immediately following the Annual Meeting. Dr. Friere's appointment represents a continuation of leadership development within the Board, and investors will be keen to understand her vision and strategic priorities for Biogen. While the filing does not provide details on the specific reasons for Ms. Dorsa's departure beyond her decision not to seek re-election, the smooth transition to Dr. Friere suggests continued stability and a focused approach to governance.

Feb 11, 2026 10-K

BIOGEN INC. Annual Report, Year Ended Dec 31, 2025

Biogen's FY2025 10-K shows a company in transition: total revenue grew 2.2% to $9.89 billion, but product revenue fell 1.3% to $7.12 billion as MS franchise erosion (down 7.1%, driven by TECFIDERA generics and TYSABRI biosimilar competition) offset growth in rare disease (up 8.4%) and new launches. Diluted EPS fell 21.4% to $8.79, reflecting higher acquired IPR&D and upfront/milestone expense ($471.8 million, up from $61.5 million), a $104.9 million royalty cost charge tied to a litigation matter, $139.5 million of other litigation-related expense (including the Convergence settlement in principle), and a $52.9 million ROU asset impairment on the Reata Plano lease. Cash generation weakened: operating cash flow fell to $2.2 billion from $2.9 billion, partly due to roughly $864 million of tax payments. Cash, equivalents and marketable securities rose to $4.2 billion, helped by $200 million of Royalty Pharma litigation-related funding for litifilimab and $1.75 billion of new senior notes that refinanced the 2025 maturity. Total borrowings were essentially flat at $6.3 billion, and the $2.1 billion remaining buyback authorization went unused in 2025. Looking ahead, management expects continued MS revenue decline, growth in rare disease (SKYCLARYS, QALSODY), flat SPINRAZA, and a slight increase in core R&D in 2026, with relatively flat SG&A. Key catalysts include the April 3, 2026 PDUFA for high-dose SPINRAZA, the May 24, 2026 PDUFA for LEQEMBI IQLIK starting dose, late-stage readouts for felzartamab, litifilimab and zorevunersen, and the 2026 Phase 3 start for salanersen. Risks include pricing pressure from the IRA and MFN policy, ongoing litigation (including a $124.3 million Genentech judgment under appeal and a German tax assessment of about $246.5 million), and dependence on the Eisai LEQEMBI collaboration.

Feb 6, 2026 8-K

BIOGEN INC. 8-K Report, Financial Results (Feb 6, 2026)

Biogen reported fourth quarter and full year 2025 results on February 6, 2026, with full year total revenue of $9.9 billion (up 2% year-over-year) and full year Non-GAAP diluted EPS of $15.28, above the upper end of its $14.50 to $15.00 guidance range. Fourth quarter results were weaker: total revenue fell 7% to $2.28 billion, and GAAP diluted EPS was $(0.33), driven by a roughly $131 million litigation charge and a $52.9 million impairment of a right-of-use asset. Non-GAAP diluted EPS fell 42% to $1.99. The core multiple sclerosis franchise continues to decline (MS product revenue down 7% for the full year and 14% in the fourth quarter), while growth products such as LEQEMBI, SKYCLARYS, and ZURZUVAE are increasing, and growth product revenue rose 19% for the full year. Management guided 2026 Non-GAAP diluted EPS to $15.25 to $16.25, which implies roughly flat to modestly higher earnings despite a mid-single-digit decline in total revenue. The guidance excludes acquired IPR&D, business development, and pending litigation. Biogen ended 2025 with about $4.2 billion in cash and $6.3 billion in total debt, for net debt of about $2.0 billion. Full year free cash flow was about $2.1 billion. The pipeline news flow is a key near-term driver: LEQEMBI IQLIK subcutaneous initiation has a PDUFA date of May 24, 2026, litifilimab received Breakthrough Therapy Designation in cutaneous lupus, and two Phase 3 lupus readouts are expected in Q4 2026. The filing is furnished under Item 2.02 and is not deemed filed for Section 18 purposes. Investors should weigh the strong full year earnings and cash generation against the fourth quarter GAAP loss, the ongoing erosion of MS revenue, and the dependence on pipeline readouts in 2026 and beyond.

Feb 6, 2026 8-K

BIOGEN INC. 8-K Report, Financial Results (Jan 14, 2026)

Biogen Inc. has filed an 8-K report providing preliminary unaudited estimates for its fourth quarter of 2025 financial results. The company anticipates a significant charge of approximately $222 million on a pre-tax basis related to acquired in-process research and development, upfront, and milestone expenses. This is expected to reduce both GAAP and non-GAAP net income per diluted share by roughly $1.26. Investors should note that these are preliminary estimates and subject to change as financial closing procedures are completed. The company emphasizes the forward-looking nature of these statements and the inherent risks and uncertainties associated with such projections, urging investors to consult detailed risk factors in their SEC filings.

Jan 14, 2026 8-K

BIOGEN INC. 8-K Report, Financial Results (Oct 30, 2025)

Biogen reported third quarter 2025 results on October 30, 2025, with total revenue of $2.53 billion, up 3% year-over-year (2% at constant currency), and GAAP diluted EPS of $3.17, up 19%. Non-GAAP diluted EPS was $4.81, up 18%. Growth was led by launch products: LEQEMBI global in-market sales were approximately $121 million (up 82%), SKYCLARYS global revenue was about $133 million (up 30%), and ZURZUVAE revenue was about $55 million. The MS franchise was flat at constant currency, supported by a favorable gross-to-net adjustment and VUMERITY strength, while TECFIDERA faced continued generic erosion in Europe. Revenue from contract manufacturing and other sources fell 35%, and Biogen's reported Q3 GAAP cost of sales included a $104 million charge tied to a TYSABRI royalty judgment (Genentech claim). The most important change for investors is the revised 2025 Non-GAAP EPS guidance of $14.50 to $15.00, down from $15.50 to $16.00 in July. Biogen raised its underlying outlook by about $0.25, but expects roughly a $1.25 per-share hit in Q4 from acquired IPR&D tied to business development deals expected to close that quarter, including the Vanqua Bio C5aR1 license ($70 million upfront) and the pending Alcyone Therapeutics acquisition ($85 million upfront plus milestones). Full-year 2025 total revenue guidance was nudged up to approximately flat to +1% at constant currency, though management flagged increased ex-U.S. MS competition in Q4. Pipeline and balance sheet news was also notable. Management highlighted the FDA resubmission of high-dose SPINRAZA with a PDUFA date of April 3, 2026, full enrollment of both litifilimab Phase 3 lupus studies with data now expected in H2 2026, and a rolling FDA submission for LEQEMBI IQLIK treatment initiation. Biogen ended the quarter with about $4.0 billion in cash and $6.3 billion in total debt, leaving net debt of roughly $2.3 billion. Operating cash flow was about $1.3 billion and free cash flow about $1.2 billion in the quarter.

Oct 30, 2025 10-Q

BIOGEN INC. Quarterly Report for Q3 Ended Sep 30, 2025

Biogen Inc. reported solid financial results for the third quarter and first nine months of 2025, demonstrating revenue growth driven by key product lines. Total revenue increased by 2.8% year-over-year to $2.53 billion for the quarter, with product revenue showing a 4.4% increase to $1.85 billion. This growth was primarily fueled by the Rare Disease segment, up 7.8%, and a 0.7% increase in Multiple Sclerosis (MS) revenue, with VUMERITY and TYSABRI showing particular strength, despite continued generic competition for TECFIDERA. The company also saw substantial growth in its Alzheimer's collaboration revenue, up 129.6% year-over-year, reflecting increased sales of LEQEMBI. Despite revenue growth, the company faced increased costs, notably in Cost of Sales, up 5.6% driven by a litigation charge and higher SKYCLARYS inventory step-up amortization. However, Research and Development (R&D) expenses decreased by 15.5%, partly due to cost-saving measures and R&D funding from Royalty Pharma, while Selling, General, and Administrative (SG&A) expenses saw a modest increase to support product launches. Diluted earnings per share (EPS) rose by 19.2% to $3.17, reflecting the revenue growth and improved R&D efficiency. Biogen's liquidity remains strong, with cash, cash equivalents, and marketable securities increasing to $4.0 billion.

Oct 30, 2025 8-K

BIOGEN INC. 8-K Report, Financial Results (Oct 14, 2025)

Biogen Inc. (BIIB) has filed an 8-K report to disclose preliminary financial information for the third quarter of 2025. The company anticipates a pre-tax charge of approximately $2 million related to acquired in-process research and development, upfront, and milestone expenses. This is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.01 for the quarter. This specific expense category was introduced in Q1 2025 and encompasses costs from collaboration and license agreements, including upfront and milestone payments, and in some cases, premiums on equity securities and asset acquisitions of acquired in-process R&D. Biogen notes that such expenses are difficult to forecast due to their inherent uncertainty in timing and magnitude. Investors should be aware that these are preliminary estimates and subject to change upon finalization of financial closing procedures.

Oct 14, 2025 8-K

BIOGEN INC. 8-K Report, Financial Results (Jul 31, 2025)

Biogen reported second-quarter 2025 results on July 31, 2025, with total revenue of $2.65 billion, up 7% year over year (8% at constant currency). GAAP diluted EPS was $4.33 (up 8%) and Non-GAAP diluted EPS was $5.47 (up 4%). Results were helped by launch products: LEQEMBI U.S. in-market sales of about $63 million (up 20% sequentially), SKYCLARYS global revenue of about $130 million, and ZURZUVAE revenue of $46 million (up 68% sequentially). Revenue was also lifted by contract manufacturing and Alzheimer's collaboration revenue, and the U.S. MS business was resilient, aided by roughly $75 million of favorable gross-to-net and inventory timing. Core multiple sclerosis product revenue still declined 4%, and Biogen flagged expected ex-U.S. MS competition in the second half, particularly for TECFIDERA in Europe. Management raised full-year 2025 guidance. Non-GAAP diluted EPS is now $15.50 to $16.00, up from $14.50 to $15.50, which reflects a $0.87 benefit from the stronger outlook partly offset by about $0.12 from the City Therapeutics transaction. Total revenue is now expected to be roughly flat at constant currency versus 2024, improved from a mid-single-digit decline. Biogen also expects minimal contract manufacturing revenue in Q4 2025 due to planned plant maintenance. The Fit for Growth program is expected to yield about $800 million net savings by year-end 2025, and combined Non-GAAP R&D and SG&A is expected at about $4.0 billion. Balance sheet and cash flow were weaker in the quarter. Operating cash flow was about $161 million, held down by roughly $745 million of cash tax payments, yielding free cash flow of about $134 million. Biogen ended the quarter with about $2.8 billion of cash against $6.3 billion of debt, for net debt of about $3.5 billion, up from the prior year as notes payable rose from $4.5 billion to $6.3 billion. Pipeline progress included salanersen moving to registrational studies in SMA and initiation of three Phase 3 felzartamab studies in kidney disease. Biogen also plans a September 3, 2025 investor event focused on its late-stage lupus assets.

Jul 31, 2025 10-Q

BIOGEN INC. Quarterly Report for Q2 Ended Jun 30, 2025

Biogen Inc. reported total revenue of $2,645.5 million for the three months ended June 30, 2025, an increase of 7.3% compared to the same period in the prior year. This growth was primarily driven by a significant increase in Alzheimer's collaboration revenue (LEQEMBI) and contract manufacturing, royalty, and other revenue. However, product revenue experienced a slight decline of 1.1%, largely due to ongoing competition for its Multiple Sclerosis (MS) portfolio, particularly from generic versions of TECFIDERA and a TYSABRI biosimilar. Net income attributable to Biogen Inc. rose to $634.8 million, or $4.33 per diluted share, up from $583.6 million, or $4.00 per diluted share, in the prior year's quarter. This improvement was supported by the top-line growth and a substantial reduction in Research and Development (R&D) expenses, partially offset by higher cost of sales and selling, general, and administrative (SG&A) expenses. The company ended the period with a strong liquidity position, with cash and cash equivalents totaling $2.8 billion.

Jul 31, 2025 8-K

BIOGEN INC. 8-K Report, Financial Results (Jul 7, 2025)

Biogen Inc. (BIIB) has issued a Current Report on Form 8-K disclosing anticipated financial results for the second quarter of 2025. The company expects to incur approximately $46 million in acquired in-process research and development, upfront, and milestone expenses on a pre-tax basis. This charge is estimated to reduce both GAAP and non-GAAP earnings per diluted share by approximately $0.26 for the quarter.

Jul 7, 2025 8-K

BIOGEN INC. 8-K Report, Shareholder Vote Results (Jun 23, 2025)

Biogen Inc. (BIIB) filed an 8-K on June 23, 2025, reporting the final voting results from its 2025 Annual Meeting of Stockholders held on June 17, 2025. The primary focus of this filing is the outcome of shareholder votes on key corporate governance matters, including the election of directors and the ratification of the independent auditor. The results indicate strong shareholder support for the company's proposed slate of eleven director nominees and the reappointment of PricewaterhouseCoopers LLP as its auditor for the upcoming fiscal year. Additionally, shareholders provided an advisory vote on executive compensation, the results of which are detailed in the filing.

Jun 23, 2025 8-K

BIOGEN INC. 8-K Report, Corporate Update (May 12, 2025)

Biogen Inc. (BIIB) announced the completion of a significant debt offering, successfully issuing and selling $1.75 billion in aggregate principal amount of senior unsecured notes on May 12, 2025. This offering consists of three tranches: $400 million of 5.050% Senior Notes due 2031, $650 million of 5.750% Senior Notes due 2035, and $700 million of 6.450% Senior Notes due 2055. The company intends to use the net proceeds from this issuance, along with existing cash, to fully retire its outstanding $1.75 billion of 4.050% Senior Notes due 2025. This strategic refinancing aims to extend Biogen's debt maturity profile and potentially optimize its interest expense.

May 12, 2025 10-Q

BIOGEN INC. Quarterly Report for Q1 Ended Mar 31, 2025

Biogen Inc. reported total revenue of $2.43 billion for the first quarter of 2025, a 6.1% increase year-over-year, driven primarily by growth in rare disease products and higher contract manufacturing revenue. However, net income attributable to Biogen Inc. decreased significantly by 39.0% to $240.5 million, or $1.64 per diluted share, compared to $393.4 million, or $2.70 per diluted share, in the prior year's quarter. This decline was largely due to increased acquired in-process R&D, upfront and milestone expenses, primarily related to the acquisition of HI-Bio and collaboration with Stoke Therapeutics, as well as higher cost of sales. Despite the decrease in profitability, the company's cash position strengthened to $2.6 billion. Key product segments showed mixed performance. While revenue from multiple sclerosis (MS) products declined 11.4% due to increased competition, particularly from generics and biosimilars, rare disease revenue surged by 32.9%. This growth in rare diseases was bolstered by strong performance from SPINRAZA, along with contributions from new launches like SKYCLARYS and QALSODY. Alzheimer's collaboration revenue from LEQEMBI also saw a substantial increase, reflecting its ongoing market penetration. The company also announced a new corporate headquarters lease in Cambridge, MA, and continued to advance its pipeline through strategic collaborations and research funding.

May 1, 2025 8-K

BIOGEN INC. 8-K Report, Financial Results (May 1, 2025)

Biogen reported first quarter 2025 total revenue of $2.431 billion, up 6% year-over-year (8% at constant currency), with GAAP diluted EPS of $1.64 (down 39%) and Non-GAAP diluted EPS of $3.02 (down 18%). The EPS decline is largely driven by a $165 million upfront payment to Stoke Therapeutics for rights to zorevunersen (Dravet syndrome), which reduced EPS by roughly $0.95. Product revenue grew only 1% at actual currency (3% at constant currency), aided partly by timing of SPINRAZA shipments. Multiple sclerosis revenue fell 11% to $953 million, while rare disease revenue rose 33% to $563 million, and launch products such as LEQEMBI, SKYCLARYS and ZURZUVAE showed growth. Management updated full-year 2025 Non-GAAP diluted EPS guidance to $14.50-$15.50 from $15.25-$16.25, reflecting the Stoke payment partially offset by a $0.20 foreign exchange benefit. The company continues to expect total 2025 revenue to decline by a mid-single-digit percentage at constant currency, as MS erosion is expected to be partly offset by launch products. Management stated the outlook is not currently expected to be materially affected by potential pharmaceutical tariffs, citing U.S. manufacturing footprint and inventory positions, though the tariff landscape remains uncertain. Balance sheet and cash flow remained solid, with Q1 operating cash flow of $259 million, free cash flow of $222 million, cash of $2.6 billion, total debt of $6.3 billion and net debt of about $3.7 billion. Pipeline news included a Phase 3 start for felzartamab in late antibody-mediated rejection, plans for additional felzartamab Phase 3 trials in 2025, FDA Fast Track designation for BIIB080, and full enrollment of the Phase 2b LUMA study for BIIB122 with readout expected in 2026.

May 1, 2025 8-K

BIOGEN INC. 8-K Report, Financial Results (Feb 12, 2025)

Biogen's 8-K (furnished under Item 2.02) reports fourth quarter and full year 2024 results and provides 2025 guidance. Full-year 2024 total revenue was $9.7 billion, down 2% year over year, while GAAP diluted EPS rose 40% to $11.18 (helped by an $88.6 million gain on sale of a priority review voucher and lower operating charges) and non-GAAP diluted EPS rose 12% to $16.47. Fourth-quarter revenue of $2.5 billion grew 3%, with non-GAAP EPS of $3.44 up 17%. Multiple sclerosis product revenue continued to decline (down 7% for the year and 8% in Q4), offset in part by growth in rare disease (up 10%, led by SKYCLARYS and SPINRAZA) and early launches such as LEQEMBI and ZURZUVAE. The key forward-looking item is 2025 guidance: non-GAAP diluted EPS of $15.25 to $16.25, which implies a decline from 2024's $16.47, and total revenue expected to fall by a mid-single-digit percentage at constant currency. Management expects further MS erosion to be only partially offset by launches. Cost discipline is a central theme: the Fit for Growth program is targeted at roughly $800 million in net savings by the end of 2025, with about $400 million already achieved, and combined non-GAAP R&D and SG&A are guided to about $3.9 billion. Management also expects operating margin to be roughly flat. Balance sheet and cash generation remain solid, with full-year free cash flow of about $2.7 billion, year-end cash of about $2.4 billion, total debt of about $6.3 billion, and net debt of about $3.9 billion. Pipeline news included pruning of four early-stage programs, a Royalty Pharma funding deal of up to $250 million for litifilimab, and regulatory milestones for LEQEMBI subcutaneous maintenance (PDUFA August 31, 2025) and SPINRAZA higher dosing (PDUFA September 22, 2025). Guidance excludes any future acquisitions, business development, litigation, or tax and healthcare reform effects.

Feb 12, 2025 10-K

BIOGEN INC. Annual Report, Year Ended Dec 31, 2024

Biogen's FY2024 Form 10-K (filed February 12, 2025) shows a company in transition: total revenue fell 1.6% to $9.68 billion, while diluted EPS rose 40.3% to $11.18, helped by lower R&D and SG&A spending under the Fit for Growth cost program and by a $1.6 billion increase in amortization and impairment charges that was more than offset elsewhere. Product revenue was essentially flat at $7.21 billion, with MS revenue down 6.7% to $4.35 billion because of TECFIDERA generic erosion, TYSABRI competition and lower interferon demand. Rare disease grew 10.3% to $1.99 billion, led by the first full year of SKYCLARYS ($382.5 million) and ZURZUVAE, though this was partly offset by lower SPINRAZA sales outside the U.S. The balance sheet and cash flow improved. Operating cash flow rose 86% to $2.88 billion, cash and equivalents reached $2.38 billion, and the company repaid $650 million of its 2023 term loan. Total borrowings fell to $6.30 billion, but $1.75 billion of 4.05% Senior Notes mature in September 2025, which pushed current liabilities up sharply and reduced working capital to $1.93 billion. The company completed the $1.15 billion HI-Bio acquisition, which added the felzartamab pipeline and roughly $650 million of potential milestones, and sold its rare pediatric priority review voucher for $88.6 million net. No share repurchases were made in 2024, leaving about $2.1 billion authorized. The main investor concerns are the continued decline of the MS franchise, biosimilar and generic pressure on RITUXAN, TECFIDERA and TYSABRI, IRA-related revenue headwinds estimated at $50-100 million for 2025, and the LEQEMBI launch, which still depends on EU and Australia regulatory outcomes. Management expects MS revenue to keep declining in 2025 while rare disease grows. Core R&D is expected to fall, but the company is still funding pipeline investments and facing a 2025 debt maturity wall.

Feb 12, 2025 8-K

BIOGEN INC. 8-K Report, Executive Changes (Jan 15, 2025)

Biogen Inc. has announced a key leadership transition in its finance department, effective March 1, 2025. Sean Godbout has been appointed as the new Vice President, Chief Accounting Officer & Global Corporate Controller, and will also serve as the Company's principal accounting officer. This appointment is part of a broader leadership evolution within the finance team, as Robin Kramer, the current Chief Accounting Officer, transitions to the role of Chief Financial Officer upon the retirement of Michael McDonnell on the same date. Mr. Godbout brings extensive experience to his new role, having been with Biogen since 2007 and most recently serving as Global Corporate Controller. His compensation package includes a base salary of $400,000, eligibility for an annual bonus plan, and long-term incentive grants. The filing also outlines the severance benefits Mr. Godbout is entitled to under the company's executive severance plan for Vice Presidents, which includes provisions for termination without cause and in connection with a corporate change of control. Investors should note this as a routine but important update regarding financial leadership continuity.

Jan 15, 2025 10-Q

BIOGEN INC. Quarterly Report for Q3 Ended Sep 30, 2024

Biogen Inc. reported net income of $388.5 million, or $2.66 per diluted share, for the third quarter of 2024, a significant improvement from a net loss of $68.1 million in the same period last year. This turnaround was driven by a substantial decrease in total costs and expenses, including lower R&D and SG&A expenses, partly due to the phasing out of acquisition-related equity compensation costs recognized in the prior year. Total revenue saw a slight decrease of 2.5% to $2.47 billion, mainly impacted by a 9.1% decline in Multiple Sclerosis (MS) product revenue due to increased competition, particularly for TYSABRI and TECFIDERA. The company successfully completed the acquisition of HI-Bio for $1.15 billion in July 2024, adding felzartamab to its pipeline for severe immune-mediated diseases. This strategic move is expected to bolster Biogen's immunology and rare disease portfolios. While overall MS revenue continues to face challenges from generic competition and shifting patient preferences towards higher efficacy therapies, the Rare Disease segment showed strong growth, primarily driven by the initial sales of SKYCLARYS, acquired through the Reata transaction in late 2023. Biogen's financial position remains solid with cash and cash equivalents increasing to $1.7 billion. The company generated $2.1 billion in operating cash flow for the first nine months of the year. Despite ongoing competitive pressures in key therapeutic areas, Biogen's focus on pipeline advancement and strategic acquisitions positions it to navigate the evolving biopharmaceutical landscape. Investors should monitor the performance of newer products like SKYCLARYS and the progress of pipeline assets such as felzartamab, while also considering the continued challenges in the MS segment.

Oct 30, 2024 8-K

BIOGEN INC. 8-K Report, Financial Results (Oct 30, 2024)

Biogen reported third quarter 2024 results on October 30, 2024, with total revenue of $2.47 billion, down 3% year over year, and GAAP diluted EPS of $2.66 versus a GAAP loss of $(0.47) a year earlier. Non-GAAP diluted EPS was $4.08, down 6% from $4.36. The top-line decline was driven by a 9% drop in multiple sclerosis (MS) product revenue, which was partly offset by 10% growth in rare disease revenue (SPINRAZA, SKYCLARYS, QALSODY), a 6% rise in anti-CD20 program revenue, and new launches including ZURZUVAE (about $22 million) and LEQEMBI (about $67 million global in-market sales). Contract manufacturing, royalty and other revenue fell 18%. Margins improved: non-GAAP cost of sales fell to 24% of revenue from 26%, and GAAP and non-GAAP R&D and SG&A declined sharply year over year, largely because of one-time 2023 Reata equity compensation charges and ongoing Fit for Growth cost reductions. Management raised full-year 2024 non-GAAP diluted EPS guidance to $16.10 to $16.60 from $15.75 to $16.25, implying about 11% growth at the midpoint versus 2023. Total revenue is still expected to decline by a low-single-digit percentage, and operating income is now expected to grow at a high-teens percentage. Pipeline news was a major focus: the dapirolizumab pegol Phase 3 trial in lupus met its primary endpoint, felzartamab received FDA Breakthrough Therapy Designation for antibody-mediated rejection, and nusinersen's higher-dose regimen showed statistically significant improvement in DEVOTE. Biogen and Sage also decided to stop developing zuranolone for major depressive disorder. From a balance sheet perspective, Q3 free cash flow was about $901 million, and net debt was about $4.6 billion ($6.3 billion total debt against $1.7 billion cash and securities). No shares were repurchased in the quarter, leaving about $2.1 billion under the authorization. Investors should watch how fast new launches can offset the MS erosion, the timing of the lupus and nusinersen filings, and whether the EPS raise holds given the ongoing revenue decline.

Oct 30, 2024 8-K

BIOGEN INC. 8-K Report, Executive Changes (Oct 30, 2024)

Biogen Inc. (Nasdaq: BIIB) announced on October 28, 2024 that Chief Financial Officer Michael McDonnell will retire effective February 28, 2025. Robin Kramer, the company's current Chief Accounting Officer and head of Global Business Services and Treasury, will succeed him as CFO upon his retirement. The 8-K was filed to disclose this leadership change under Item 5.02 (departure and appointment of certain officers) and to furnish the related press release under Item 7.01 (Regulation FD). The announcement is a planned succession rather than an abrupt departure, and McDonnell is staying on through the transition period to support a handover. McDonnell has served as CFO since August 2020 and is credited by CEO Christopher Viehbacher with leading the "Fit for Growth" program to realign Biogen's cost structure with its revenue base, redeploying capital toward growth areas, and supporting recent late-stage asset acquisitions. Kramer, age 59, joined Biogen in 2018 and has held the Chief Accounting Officer role since 2020, giving her deep familiarity with the company's finance, treasury, procurement, and M&A work. Her background includes senior finance roles at Hertz, Fisher Scientific, and The Gillette Company, and prior audit partner positions at Deloitte, Ernst & Young, and Arthur Andersen. For investors, the filing signals continuity rather than a strategic shift: the successor is an internal candidate with direct exposure to the company's capital allocation and M&A activity. Compensation terms set for Kramer include a $750,000 base salary, an 80% target bonus, and a 2025 long-term incentive target of $3.75 million, along with a tiered severance framework tied to termination and change-in-control scenarios. The filing does not disclose any change in financial guidance or results.

Oct 30, 2024 8-K

BIOGEN INC. 8-K Report, Executive Changes (Sep 12, 2024)

Biogen Inc. announced an expansion of its Board of Directors with the appointment of two new independent directors, Dr. Lloyd Minor and Professor Sir Menelas Pangalos. Dr. Minor's appointment is effective October 1, 2024, while Professor Sir Pangalos will join on January 1, 2025. Both are expected to serve until the company's 2025 Annual Meeting of Stockholders. These appointments bring significant expertise to Biogen's board, with Dr. Minor being a prominent figure in academic medicine and university leadership, and Professor Sir Pangalos having extensive experience in neuroscience research and development within the pharmaceutical industry. Investors should view these additions as a positive step towards strengthening the board's strategic oversight and scientific acumen, potentially enhancing the company's innovation and long-term growth prospects.

Sep 12, 2024 8-K

BIOGEN INC. 8-K Report, Material Agreement (Aug 14, 2024)

Biogen Inc. (BIIB) announced on August 14, 2024, through an 8-K filing, the entry into a new $1.5 billion, five-year unsecured, revolving credit facility with Bank of America, N.A. This new facility replaces the Company's previous credit agreement. As of the closing date, no funds had been drawn under this new facility, indicating Biogen maintains a strong liquidity position. The new credit agreement provides Biogen with significant financial flexibility for general corporate purposes. The interest rates are variable, tied to benchmark rates like SOFR, EURIBOR, etc., plus an applicable margin that depends on the Company's debt ratings. The facility includes sub-limits for letters of credit and swing line loans. Importantly, the agreement includes a financial covenant requiring Biogen to maintain a consolidated leverage ratio of no more than 3.75 to 1.0, with a temporary increase allowed to 4.25 to 1.0 in case of material acquisitions.

Aug 14, 2024 10-Q

BIOGEN INC. Quarterly Report for Q2 Ended Jun 30, 2024

Biogen Inc. reported a slight increase in total revenue for the three months ended June 30, 2024, reaching $2,464.9 million, a 0.4% rise year-over-year. This was primarily driven by a 2.9% increase in product revenue, largely from the rare disease segment, which saw a significant boost from SKYCLARYS sales. However, revenue from contract manufacturing, royalty, and other sources declined by 31.7%. Diluted earnings per share decreased by 1.7% to $4.00, reflecting higher amortization costs related to the Reata acquisition's intangible assets and a substantial increase in 'Other (income) expense, net,' which more than offset a decrease in R&D and cost of sales. The company also announced the completion of the HI-Bio acquisition for $1.15 billion, funded by existing cash, and the sale of a priority review voucher for $103.0 million, contributing to a substantial increase in cash and cash equivalents to $1.9 billion.

Aug 1, 2024 8-K

BIOGEN INC. 8-K Report, Financial Results (Aug 1, 2024)

Biogen reported second-quarter 2024 results on August 1, 2024, with total revenue of $2.46 billion, flat year-over-year at actual currency and up 1% at constant currency. GAAP diluted EPS was $4.00 (down 2%), while Non-GAAP diluted EPS was $5.28 (up 31%). The headline EPS improvement is flattered by an approximately $0.52 per share benefit from selling one of the company's two priority review vouchers (PRV), with an $89 million gain. Excluding the PRV sale, GAAP diluted EPS declined 14% and Non-GAAP diluted EPS rose 18%, so investors should look past the reported headline growth when judging underlying operating momentum. Core pharmaceutical revenue (product revenue plus LEQEMBI) grew 5% at actual currency and 6% at constant currency. Growth was driven by rare disease (SKYCLARYS at $100 million and SPINRAZA-led franchise revenue up 22%) and new launches, including LEQEMBI with roughly $40 million of global in-market sales in the quarter. These gains offset a 5% decline in multiple sclerosis product revenue, which remains the core pressure point. Operating efficiency improved, with non-GAAP R&D down 21% and no idle capacity charges in the quarter, supported by the Fit for Growth and R&D prioritization programs. Management raised full-year 2024 Non-GAAP EPS guidance to $15.75 to $16.25, from $15.00 to $16.00, implying roughly 9% growth at the midpoint versus 2023. Total revenue is now expected to decline by a low-single-digit percentage (improved from low-to-mid single digits), and operating income is expected to grow in the mid-to-high teens. The company also completed the acquisition of Human Immunology Biosciences for $1.15 billion, repaid its $1.0 billion 2023 term loan, and ended the quarter with net debt of about $4.4 billion. No shares were repurchased in the quarter, leaving $2.1 billion under the existing authorization.

Aug 1, 2024 8-K

BIOGEN INC. 8-K Report, Bylaw Amendment (Jun 25, 2024)

Biogen Inc. filed an 8-K on June 25, 2024, detailing the outcomes of its 2024 Annual Meeting of Stockholders held on June 20, 2024. The most significant event from an investor perspective was the approval of an amendment to the Company's Certificate of Incorporation to allow for the exculpation of certain company officers, to the extent permitted by Delaware law. This change, which was previously approved by the Board of Directors, aims to provide a layer of protection for officers against certain liabilities. Additionally, the filing provides the final voting results for all proposals presented at the meeting. These included the election of nine directors to the Board, the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2024, an advisory vote on executive compensation, and the approval of two equity incentive plans: the 2024 Omnibus Equity Plan and the 2024 Employee Stock Purchase Plan. All proposals received substantial support from stockholders, indicating general alignment with management's decisions and governance.

Jun 25, 2024 8-K

BIOGEN INC. 8-K Report, Financial Results (Apr 24, 2024)

Biogen's first quarter 2024 results (reported April 24, 2024) show a mixed picture: GAAP diluted EPS rose 1% to $2.70 and non-GAAP diluted EPS rose 8% to $3.67, but total revenue fell 7% to $2.29 billion and product revenue fell 3% to $1.71 billion. The earnings improvement was driven by cost discipline rather than top-line growth. Non-GAAP R&D fell about 22% and non-GAAP SG&A fell about 6%, with no idle capacity charges in the quarter (versus roughly $45 million in Q1 2023). Contract manufacturing, royalty and other revenue dropped 39%, which accounts for much of the total revenue decline. Operating income grew 10% on a GAAP basis and 24% on a non-GAAP basis. The new launches are early but showing momentum. LEQEMBI in-market sales were about $19 million, nearly triple Q4 2023, and patients on therapy rose roughly 2.5 times since year-end 2023. SKYCLARYS generated $78 million globally, with the E.U. launch now underway, and ZURZUVAE contributed about $12 million. Offsetting these gains, MS product revenue fell 4% and SPINRAZA ex-U.S. revenue fell 35%, reflecting shipment timing and competition. Management reaffirmed full-year 2024 non-GAAP EPS guidance of $15.00 to $16.00 (about 5% growth at the midpoint), while expecting total revenue to decline by a low- to mid-single digit percentage. The balance sheet remains leveraged. Net debt was about $5.5 billion at quarter-end, against $1.1 billion in cash and $6.5 billion in total debt. Free cash flow was $507 million, and Biogen received about $437 million from Samsung BioLogics after quarter-end. No shares were repurchased in the quarter, leaving $2.1 billion under the authorization. Investors should weigh the margin and EPS improvement against continued revenue erosion and the pace at which new launches must replace declining MS franchise sales.

Apr 24, 2024 10-Q

BIOGEN INC. Quarterly Report for Q1 Ended Mar 31, 2024

Biogen Inc. (BIIB) reported a decrease in total revenue for the first quarter of 2024, down 7.0% year-over-year to $2.29 billion. This decline was primarily driven by a significant drop in contract manufacturing, royalty, and other revenue, which fell 38.5% to $184.6 million. Product revenue also saw a modest decrease of 2.9% to $1.71 billion, largely due to ongoing generic competition impacting Multiple Sclerosis (MS) revenues, which decreased by 4.4%, and a decrease in Rare Disease revenue by 4.4%. Despite the revenue challenges, the company managed to increase its net income to $393.4 million, a slight rise from $387.9 million in the prior year's quarter, resulting in diluted earnings per share of $2.70, up from $2.67. The company also demonstrated strong operational cash flow generation of $553.2 million.

Apr 24, 2024 10-K

BIOGEN INC. Annual Report, Year Ended Dec 31, 2023

Biogen's FY2023 10-K shows a company in transition: total revenue fell 3.3% to $9.84 billion and diluted EPS dropped 61.8% to $7.97, as multiple sclerosis franchise erosion (MS product revenue down 14.1%, driven by TECFIDERA generics) outpaced growth elsewhere. Net income attributable to Biogen was $1.16 billion versus $3.05 billion in 2022, which included a $1.5 billion gain on the Samsung Bioepis sale and a $900 million litigation charge. Results were also affected by roughly $393 million of one-time equity compensation tied to the September 2023 Reata acquisition, $212.5 million of Fit for Growth restructuring charges, and $1.3 billion of SKYCLARYS inventory step-up adjustments flowing through inventory. The balance sheet and capital allocation changed materially. Biogen spent roughly $6.9 billion on the Reata acquisition, funded largely from cash and a $1.0 billion term loan. Cash and marketable securities fell from $5.6 billion to $1.0 billion, total borrowings rose to $6.9 billion, and no share repurchases were made in 2023, leaving about $2.1 billion under the authorization. Operating cash flow was $1.55 billion. Management expects MS revenue to keep declining in 2024, with growth driven by LEQEMBI, SKYCLARYS and the Fit for Growth program, which targets $800 million in net operating expense savings by 2025. Key risks include continued generic and biosimilar competition, uncertain LEQEMBI launch economics and reimbursement, IRA drug pricing pressure, an underutilized Solothurn manufacturing plant generating excess-capacity charges, and ongoing litigation including ADUHELM securities actions, a Genentech royalty claim of about $88 million, and government investigations. The company also announced it is exploring strategic options for its biosimilars business.

Feb 14, 2024 8-K

BIOGEN INC. 8-K Report, Financial Results (Feb 13, 2024)

Biogen reported fourth quarter and full year 2023 results on February 13, 2024. Q4 2023 total revenue was $2.39 billion, down 6% year over year (down 5% at constant currency), with GAAP diluted EPS of $1.71 and Non-GAAP diluted EPS of $2.95 (down 27%). The Non-GAAP EPS decline was driven in part by $0.35 per share of previously disclosed ADUHELM closeout costs. For full year 2023, revenue was $9.84 billion (down 3%), GAAP diluted EPS was $7.97, and Non-GAAP diluted EPS was $14.72 (down 17% from $17.67). Multiple sclerosis product revenue fell 14% for the year, while rare disease (SPINRAZA, QALSODY, SKYCLARYS) grew 1% and biosimilars grew 3%. Full year 2023 GAAP results were also affected by the Reata acquisition, including about $393 million of post-acquisition equity compensation and $240 million of amortization and impairment of acquired intangibles. Management guided 2024 Non-GAAP diluted EPS to $15.00 to $16.00, implying roughly 5% growth at the midpoint. Total revenue is expected to decline by a low- to mid-single-digit percentage, while core pharmaceutical revenue (product revenue plus Biogen's 50% share of LEQEMBI) is expected to be roughly flat, as MS erosion is offset by new launches. Contract manufacturing revenue is expected to fall significantly after batch commitments tied to the Hillerød sale were satisfied. Operating income is guided to grow at a low-double-digit percentage, supported by a better cost of sales ratio and the Fit for Growth program, which targets $1 billion in gross and $800 million in net savings by 2025. Balance sheet and cash flow were solid but leverage increased. Full year free cash flow was about $1.27 billion, but Q4 free cash flow was negative (about -$53 million) because of a $393 million payment tied to Reata equity awards. Cash and marketable securities were about $1.0 billion against roughly $6.9 billion of total debt, leaving net debt near $5.9 billion. No shares were repurchased in Q4, and about $2.1 billion remained under the existing buyback authorization.

Feb 13, 2024 8-K

BIOGEN INC. 8-K Report, Bylaw Amendment (Dec 12, 2023)

Biogen Inc. (BIIB) filed an 8-K on December 12, 2023, detailing amendments to its Fifth Amended and Restated Bylaws, effective December 6, 2023. The primary focus of these amendments is to update procedural mechanics and disclosure requirements related to stockholder meetings, particularly concerning the submission of business proposals and director nominations. These changes aim to enhance transparency and streamline the proxy solicitation process. Key updates include more stringent disclosure requirements for stockholders proposing business, such as detailing derivative or synthetic arrangements that mirror long positions in company shares. Additionally, provisions related to director nominations have been enhanced to align with Rule 14a-19 of the Securities Exchange Act, requiring significant proxy solicitation efforts (at least 67% of voting power) and specific disclosures from nominating stockholders and their nominees. The amendments also clarify procedures for meeting adjournments, quorum establishment, and the revocability of proxies.

Dec 12, 2023 8-K

BIOGEN INC. 8-K Report, Financial Results (Nov 8, 2023)

Biogen reported third quarter 2023 results on November 8, 2023, with total revenue of $2,530 million, up 1% year over year (3% at constant currency), while GAAP diluted EPS was $(0.47) and non-GAAP diluted EPS was $4.36, down 9%. The headline GAAP loss was driven largely by a $302 million net unrealized loss on strategic equity investments, $393 million of share-based compensation acceleration tied to the Reata acquisition, $76 million of restructuring charges, and a $30 million transaction and integration charge. Product revenue fell 8% to $1,805 million, with MS revenue down 14% as TECFIDERA, VUMERITY and TYSABRI declined, partially offset by growth in SPINRAZA (+4%) and biosimilars (+4%). Contract manufacturing, royalty and other revenue more than doubled to $304 million, largely reflecting LEQEMBI collaboration economics, and it now accounts for a meaningful share of top-line growth. Management highlighted the closing of the Reata Pharmaceuticals acquisition on September 26, 2023, the FDA approvals of LEQEMBI and ZURZUVAE (for postpartum depression), and the launch of a $1 billion 'Fit for Growth' cost-savings program. Full-year 2023 guidance was revised: total revenue is now expected to decline by a low-single-digit percentage (previously mid-single-digit), and non-GAAP EPS guidance was lowered to $14.50 to $15.00 from $15.00 to $16.00, reflecting roughly $0.75 of Reata dilution. Biogen also changed how it presents LEQEMBI collaboration sales and marketing expenses, moving the 50% share of those costs into SG&A rather than netting them against revenue, which affects comparability with prior periods. Financially, Biogen ended the quarter with $2,288 million in cash and marketable securities against $7,286 million of total debt, for net debt of $4,998 million. Third-quarter operating cash flow was $592 million and free cash flow was $518 million. No shares were repurchased in the quarter, leaving $2,050 million under the existing authorization. Investors will want to watch the pace of the LEQEMBI launch, the durability of MS franchise erosion, the realization of Reata-related contributions, and execution on the cost-savings program.

Nov 8, 2023 8-K

BIOGEN INC. 8-K Report, Executive Changes (Nov 8, 2023)

Biogen Inc. announced a key addition to its Board of Directors, effective January 1, 2024. Monish Patolawala has been elected as a new director, filling a vacancy and serving until the 2024 Annual Meeting. Mr. Patolawala's expertise is particularly noteworthy as he qualifies as an "audit committee financial expert," a designation important for oversight of financial reporting and internal controls. This appointment suggests a continued focus on robust financial governance and potentially strengthens the composition of the Board's Audit Committee, should he be appointed to it.

Nov 8, 2023 10-Q

BIOGEN INC. Quarterly Report for Q3 Ended Sep 30, 2023

Biogen Inc. reported a net loss of $68.1 million for the third quarter of 2023, a significant change from the $1.13 billion net income in the same period last year. This shift was primarily driven by a substantial increase in total costs and expenses, particularly R&D and SG&A expenses, largely due to one-time costs associated with the acquisition of Reata Pharmaceuticals. Total revenue saw a slight increase of 0.9% to $2.53 billion, driven by growth in contract manufacturing and royalty revenue, which offset a 8.0% decline in product revenue. The decrease in product revenue was mainly attributed to ongoing generic competition for TECFIDERA and increased competition for TYSABRI, partially offset by growth in SPINRAZA. Operationally, the company completed the significant acquisition of Reata for approximately $7.2 billion, adding SKYCLARYS, a treatment for Friedreich's Ataxia, to its portfolio. This acquisition, while strategically important, significantly impacted the company's financial results for the quarter due to associated expenses. Management is also progressing with a 'Fit for Growth' program aimed at reducing operating costs by approximately $1.0 billion by 2025 through measures including headcount reductions. The company's cash position decreased significantly due to the Reata acquisition, but Biogen maintains adequate liquidity.

Nov 8, 2023 8-K

BIOGEN INC. 8-K/A Report, Shareholder Vote Results (Sep 28, 2023)

This amendment to Biogen Inc.'s (BIIB) 8-K filing provides an update on the outcome of an advisory vote concerning the "Say-on-Frequency" proposal presented at its Annual Meeting. The company's stockholders expressed a preference for the "Say-on-Pay" advisory vote to be conducted annually. Consequently, Biogen's Board of Directors has determined that future "Say-on-Pay" votes will indeed be held every year.

Sep 28, 2023 8-K

BIOGEN INC. 8-K Report, Corporate Update (Sep 26, 2023)

On September 26, 2023, Biogen Inc. (Nasdaq: BIIB) announced via Form 8-K that it had completed its acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA). The principal asset Biogen acquires is SKYCLARYS® (omaveloxolone), the first and only FDA-approved treatment for Friedreich's ataxia (FA) in the United States, which received approval earlier in 2023. Biogen also gains additional clinical and preclinical pipeline programs. The filing itself is a brief Item 8.01 (Other Events) disclosure that incorporates the press release as Exhibit 99.1, so the substantive financial terms (purchase price, consideration structure) are not disclosed in this document. Management characterized the deal as strategically aligned with Biogen's rare disease focus and growth objectives. SKYCLARYS has been launched in the U.S., with over 1,000 patient start forms submitted as of the closing date, and its European Marketing Authorization Application is under review by the EMA. Biogen expects significant synergies with its existing rare disease portfolio and plans to update its full-year 2023 financial guidance alongside its third-quarter 2023 earnings release. From a financial perspective, Biogen guided that the acquisition will be slightly dilutive to Non-GAAP diluted EPS in 2023 (including transaction costs), roughly neutral in 2024, and significantly accretive beginning in 2025. Investors should weigh the near-term earnings drag against the longer-term accretion thesis, which depends on SKYCLARYS commercial uptake and successful execution of the integration. The filing's forward-looking statements flag risks including commercial execution, reimbursement, integration, and retention of key Reata personnel.

Sep 26, 2023 8-K

BIOGEN INC. 8-K Report, Material Agreement (Sep 1, 2023)

Biogen Inc. (BIIB) announced on September 1, 2023, its entry into a new $1.5 billion unsecured credit facility with JPMorgan Chase Bank, N.A., effective August 28, 2023. This facility is designed to fund a significant portion of the consideration for Biogen's previously announced acquisition of Reata Pharmaceuticals, Inc., as well as repay certain Reata indebtedness and related expenses. The credit facility is comprised of two tranches: a $750 million 364-day tranche (Tranche A) and a $750 million three-year tranche (Tranche B). The new credit facility replaces a previously announced bridge loan facility. The interest rates on borrowings will be tied to either Term SOFR or a Base Rate, plus an applicable margin based on Biogen's debt ratings. The agreement includes customary covenants and events of default, as well as a financial covenant requiring Biogen to maintain a maximum consolidated leverage ratio of 3.5 to 1.0, which can temporarily increase to 4.0 to 1.0 under specific circumstances related to the Reata acquisition and other material acquisitions.

Sep 1, 2023 8-K

BIOGEN INC. 8-K Report, Material Agreement (Jul 31, 2023)

Biogen Inc. (BIIB) has announced a material definitive agreement to acquire Reata Pharmaceuticals, Inc. through a merger. This strategic move involves Biogen acquiring all outstanding shares of Reata's common stock for a cash consideration of $172.50 per share, valuing the transaction at a significant amount. The merger agreement has been unanimously approved by the boards of directors of both companies, indicating strong support for the transaction. This acquisition is expected to be financed through a combination of Biogen's existing cash reserves and a new $1.5 billion bridge loan facility, demonstrating Biogen's financial capacity to complete the deal. The transaction is subject to customary closing conditions, including Reata stockholder approval and regulatory clearances. This acquisition represents a significant step in Biogen's growth strategy, likely aimed at expanding its therapeutic portfolio and market presence. Investors should monitor the progress of Reata's stockholder approval process and any regulatory reviews. The definitive agreement includes customary provisions such as representations, warranties, and covenants, along with 'no-shop' clauses to prevent Reata from soliciting competing offers, though exceptions exist for superior proposals. The 'Fit for Growth' program mentioned in the cautionary notes suggests ongoing efforts by Biogen to optimize its operations and financial structure alongside strategic acquisitions.

Jul 31, 2023 8-K

BIOGEN INC. 8-K Report, Corporate Update (Jul 28, 2023)

On July 28, 2023, Biogen (BIIB) announced a definitive agreement to acquire Reata Pharmaceuticals (RETA) for $172.50 per share in cash, implying an enterprise value of approximately $7.3 billion. The deal is structured as a merger in which a Biogen subsidiary merges into Reata, which survives as a wholly owned subsidiary. The approved board of both companies, and Biogen has signed voting and support agreements with holders of about 36% of Reata's voting power. Closing is expected in the fourth quarter of 2023, subject to Reata stockholder approval and regulatory clearances. Biogen plans to fund the purchase with cash on hand plus term debt, and the deal is not subject to a financing condition. The strategic rationale centers on Reata's lead product, SKYCLARYS (omaveloxolone), the first and only FDA-approved treatment for Friedreich's ataxia, a rare genetic neuromuscular disease. Management argues the drug complements Biogen's neuromuscular and rare disease franchise (SPINRAZA and QALSODY) and that Biogen's existing commercial infrastructure can accelerate its launch. Management also points to likely overlap with existing prescribers and expects straightforward integration, since Reata is primarily a single-asset, US-based company with limited EU operations. Composition-of-matter patent protection is cited through 2037 in the US, assuming patent term extensions. Financially, Biogen expects the deal to be slightly dilutive to Non-GAAP diluted EPS in 2023, roughly neutral in 2024, and significantly accretive beginning in 2025, including transaction costs. Biogen will update its full-year 2023 guidance with its third-quarter 2023 earnings release. Investors should weigh the upside of a near-term growth asset against the roughly $7.3 billion price, the added debt, and the execution risks in the EU regulatory review and the launch.

Jul 28, 2023 10-Q

BIOGEN INC. Quarterly Report for Q2 Ended Jun 30, 2023

Biogen Inc. reported a decrease in total revenue for the second quarter of 2023, primarily driven by a significant decline in Multiple Sclerosis (MS) product revenue due to increased generic competition for TECFIDERA and market shifts away from Interferon therapies. While Spinal Muscular Atrophy (SMA) revenue saw a slight increase, the overall product revenue was down 10.2% year-over-year. This revenue decline, coupled with an increase in cost of sales and R&D expenses, led to a substantial decrease in net income and diluted earnings per share compared to the prior year period. However, the company's cash position remains strong, with a significant increase in cash, cash equivalents, and marketable securities, bolstered by a substantial payment received from the Samsung Bioepis sale. The company also announced a new "Fit for Growth" program aimed at significant operating expense savings.

Jul 25, 2023